Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

#ESMO21 Highlights on pembro + chemo in 1st-line metastatic cervical cancer: The KEYNOTE-826 study

Nicoletta Colombo reports on key results from ESMO Congress 2021 on LBA2_PR - KEYNOTE-826: A randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer

18 Sep 2021  Presidential symposium 1

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings